Cover Image
Market Research Report

B-Cell Maturation Antigen (BCMA): Hot Target for Emerging Treatment Modalities

Published by La Merie Publishing Product code 369011
Published Content info 39 Pages
Delivery time: 1-2 business days
Price
Back to Top
B-Cell Maturation Antigen (BCMA): Hot Target for Emerging Treatment Modalities
Published: August 31, 2016 Content info: 39 Pages
Description

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the

  • Scientific rationale for BCMA-targeted therapies;
  • Preclinical proof-of-concept of BCMA blockade;
  • Clinical experience with BCMA-targeted therapies;
  • The competitive landscape of BCMA-targeted treatment modalities;
  • Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
  • Profiles of companies involved in develompent of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity. As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.

Table of Contents
Product Code: LMBR0012

Table of Contents

1. Target Background

2. Target Antigen Expression Profile

3. Preclinical Proof-of-Concept

4. Clinical Indications & Treatment Options

5. Clinical Experience with BCMA-Targeted Treatment Modalities

6. Treatment Modalities & Competitive Landscape

7. Drug & Cell Therapy Candidate Profiles

  • 7.1. CAR T-Cells
  • 7.2. Antibody-Drug Conjugate (ADC)
  • 7.3. T-Cell Redirecting Antibodies

8. Company Profiles

9. References

Back to Top